EAST Search History

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L1	2	"20070042939" and composition	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2007/03/19 18:00
L2	141	("20020198173"|"20030120071"|"20030144502"|"20030153744"|"20040006007"|"20040014108"|"20040059104"|"20040063622"|"20040097461"|"20040097462"|"20040101535"|"20040102414"|"20040167140"|"20040191824"|"20040229839"|"20040248892"|"20040259934"|"20040265969"|"20040266996"|"20050009737"|"20050026853"|"20050031588"|"20050075309"|"20050080034"|"20050090660"|"20050124532"|"20050130931"|"20050137161"|"20050148534"|"20050164960"|"20050215513"|"20050227947"|"20050261237"|"20060003951"|"20060014943"|"20060035866"|"20060040944"|"20060079478"|"20060110727"|"20060122146"|"20060122154"|"20060142238"|"20060144502"|"4814477"|"5118820"|"5405598"|"5420266"|"5462724"|"5703058"|"5767097"|"6090932"|"6130326"|"6156501"|"6232300"|"6239159"|"6372883"|"6391859"|"6455513"|"6455690"|"6479463"|"6495677"|"6509320"|"6552183"|"6555677"|"6573248"|"6642206"|"6677314"|"6677315"|"6682715"|"6683045"|"6703374"|"6753309"|"6787305"|"6787526"|"6815542"|"6897201"|"6908924"|"6914054"|"6962991"|"7018985"|"7018989"|"7081449").PN.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2007/03/19 18:00
S1	2	"20060199783"	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2007/03/19 13:38
S2	2	"20050009737"	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2007/03/19 13:22

EAST Search History

S3	2	"20060122146"	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2007/03/19 13:22
S4	2	"20070042939"	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2007/03/19 17:46
S5	4	"20030060400"	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2007/03/19 16:14
S6	108	("20020058635"|"20030050229"|"20040023240"|"20040067901"|"20040072788"|"20040110717"|"20040214844"|"20040254141"|"3798209"|"4957924"|"5026687"|"5149794"|"5157027"|"5194654"|"5223263"|"5256641"|"5372808"|"5411947"|"5463092"|"5496546"|"5543389"|"5543390"|"5543391"|"5554728"|"5610054"|"5633358"|"5633388"|"5676942"|"5711944"|"5725859"|"5738845"|"5738846"|"5747646"|"5792834"|"5830455"|"5830905"|"5834594"|"5837257"|"5846964"|"5849696"|"5869253"|"5891874"|"5905070"|"5908621"|"5922757"|"5942223"|"5980884"|"5990276"|"6004933"|"6034134"|"6043077"|"6056961"|"6348587"|"6410531"|"6420380"|"6534523"|"6660721"|"6680303"|"6777395").PN.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2007/03/19 16:14



RN 817204-37-8 CAPLUS
CN Cytidine, N-benzoyl-2'-deoxy-2'-fluoro-2'-methyl-, 3',5'-bis(trifluoroacetate), (2'R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



=> d his

(FILE 'HOME' ENTERED AT 13:15:49 ON 19 MAR 2007)

FILE 'REGISTRY' ENTERED AT 13:16:05 ON 19 MAR 2007
L1 STRUCTURE UPLOADED
L2 0 S L1 SSS SAM
L3 2 S L1 FULL

FILE 'CAPLUS' ENTERED AT 13:17:31 ON 19 MAR 2007
L4 4 S L3

FILE 'REGISTRY' ENTERED AT 13:42:33 ON 19 MAR 2007
L5 STRUCTURE UPLOADED
L6 0 S L5 SSS SAM
L7 0 S L5 FULL

FILE 'REGISTRY' ENTERED AT 14:04:04 ON 19 MAR 2007
L8 STRUCTURE UPLOADED
L9 0 S L8 SSS SAM
L10 0 S L8 FULL
L11 STRUCTURE UPLOADED
L12 0 S L11 SSS SAM
L13 STRUCTURE UPLOADED
L14 0 S L13 SSS SAM

FILE 'REGISTRY' ENTERED AT 14:10:25 ON 19 MAR 2007
L15 STRUCTURE UPLOADED
L16 0 S L15 SSS SAM
L17 11 S L15 FULL

FILE 'CAPLUS' ENTERED AT 14:10:58 ON 19 MAR 2007
L18 6 S L17

C:\Program Files\Stnexp\Queries\10828753cl6-11c.str

L15





chain nodes :
12 13 14 15 16 17 18 19
ring nodes :
1 2 3 4 5 6 7 8 9 10 11
chain bonds :
1-11 7-13 7-14 8-15 8-18 9-16 9-19 11-12 16-17
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-11 8-9 9-10 10-11
exact/norm bonds :
1-2 1-6 1-11 2-3 3-4 4-5 5-6 7-8 7-11 7-13 7-14 8-9 8-15 8-18 9-10 9-16 9-19 10-11 11-12 16-17

G2:C,O,S,N,Se

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom 11:Atom 12:CLASS 13:CLASS 14:CLASS 15:CLASS 16:CLASS 17:CLASS 18:CLASS 19:CLASS

C:\Program Files\Stnexp\Queries\10882753cl6-11.str

L8





chain nodes :
12 13 14 15 16 17 18 20 22 23 24 25 26 27
ring nodes :
1 2 3 4 5 6 7 8 9 10 11
chain bonds :
7-13 7-14 8-15 8-18 9-16 9-20 11-12 16-17 22-25 23-26 24-27
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-11 8-9 9-10 10-11
exact/norm bonds :
1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-11 7-13 7-14 8-9 8-15 8-18 9-10 9-16 9-20 10-11 11-12 16-17 22-25
23-26 24-27

G1:H,Ak

G2:C,O,S,N,Se

G3:C,H,S,N,Cl,Br,F,I,[*1],[*2],[*3]

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom 11:Atom 12:CLASS 13:CLASS 14:CLASS
15:CLASS 16:CLASS 17:CLASS 18:CLASS 20:CLASS 22:CLASS 23:CLASS 24:CLASS 25:CLASS 26:CLASS 27:CLASS 34:CLASS

C:\Program Files\Stnexp\Queries\10828753cl1-5.str

L5





chain nodes :
12 13 14 15 16 17 18 20 22 23 24 25 26 27
ring nodes :
1 2 3 4 5 6 7 8 9 10 11
chain bonds :
1-11 7-13 7-14 8-15 8-18 9-16 9-20 11-12 16-17 22-25 23-26 24-27
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-11 8-9 9-10 10-11
exact/norm bonds :
1-2 1-6 1-11 2-3 3-4 4-5 5-6 7-8 7-11 7-13 7-14 8-9 8-15 8-18 9-10 9-16 9-20 10-11 11-12 16-17
22-25 23-26 24-27

G1:H,Ak

G2:C,O,S,N,Se

G3:C,H,S,N,Cl,Br,F,I,[*1],[*2],[*3]

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom 11:Atom 12:CLASS 13:CLASS 14:CLASS
15:CLASS 16:CLASS 17:CLASS 18:CLASS 20:CLASS 22:CLASS 23:CLASS 24:CLASS 25:CLASS 26:CLASS 27:CLASS

~~09/902,316~~ 10/824,753

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssspta1600txm

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page URLs for STN Seminar Schedule - N. America
NEWS 2		"Ask CAS" for self-help around the clock
NEWS 3	DEC 18	CA/CAplus pre-1967 chemical substance index entries enhanced with preparation role
NEWS 4	DEC 18	CA/CAplus patent kind codes updated
NEWS 5	DEC 18	MARPAT to CA/CAplus accession number crossover limit increased to 50,000
NEWS 6	DEC 18	MEDLINE updated in preparation for 2007 reload
NEWS 7	DEC 27	CA/CAplus enhanced with more pre-1907 records
NEWS 8	JAN 08	CHEMLIST enhanced with New Zealand Inventory of Chemicals
NEWS 9	JAN 16	CA/CAplus Company Name Thesaurus enhanced and reloaded
NEWS 10	JAN 16	IPC version 2007.01 thesaurus available on STN
NEWS 11	JAN 16	WPIDS/WPINDEX/WPIX enhanced with IPC 8 reclassification data
NEWS 12	JAN 22	CA/CAplus updated with revised CAS roles
NEWS 13	JAN 22	CA/CAplus enhanced with patent applications from India
NEWS 14	JAN 29	PHAR reloaded with new search and display fields
NEWS 15	JAN 29	CAS Registry Number crossover limit increased to 300,000 in multiple databases
NEWS 16	FEB 15	PATDPASPC enhanced with Drug Approval numbers
NEWS 17	FEB 15	RUSSIAPAT enhanced with pre-1994 records
NEWS 18	FEB 23	KOREAPAT enhanced with IPC 8 features and functionality
NEWS 19	FEB 26	MEDLINE reloaded with enhancements
NEWS 20	FEB 26	EMBASE enhanced with Clinical Trial Number field
NEWS 21	FEB 26	TOXCENTER enhanced with reloaded MEDLINE
NEWS 22	FEB 26	IFICDB/IFIPAT/IFIUDB reloaded with enhancements
NEWS 23	FEB 26	CAS Registry Number crossover limit increased from 10,000 to 300,000 in multiple databases
NEWS 24	MAR 15	WPIDS/WPIX enhanced with new FRAGHITSTR display format
NEWS 25	MAR 16	CASREACT coverage extended

NEWS EXPRESS	NOVEMBER 10 CURRENT WINDOWS VERSION IS V8.01c, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 25 SEPTEMBER 2006.
NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS LOGIN	Welcome Banner and News Items
NEWS IPC8	For general information regarding STN implementation of IPC 8
NEWS X25	X.25 communication option no longer available

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 13:15:49 ON 19 MAR 2007

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 13:16:05 ON 19 MAR 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

McIntosh

~~09/982,315~~

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 16 MAR 2007 HIGHEST RN 926905-73-9
DICTIONARY FILE UPDATES: 16 MAR 2007 HIGHEST RN 926905-73-9

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH December 2, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

=>
Uploading C:\Program Files\Stnexp\Queries\10828753species.str

L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR



L1

G1 H,Ak

Structure attributes must be viewed using STN Express query preparation.

=> s l1 sss sam
SAMPLE SEARCH INITIATED 13:16:28 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 8 TO ITERATE

100.0% PROCESSED 8 ITERATIONS 0 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 8 TO 329
PROJECTED ANSWERS: 0 TO 0

L2 0 SEA SSS SAM L1

=> s l1 full

McIntosh

09/982,315

FULL SEARCH INITIATED 13:16:32 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 130 TO ITERATE

100.0% PROCESSED 130 ITERATIONS 2 ANSWERS
SEARCH TIME: 00.00.01

L3 2 SEA SSS FUL L1

=> d 1-2 l3

L3 ANSWER 1 OF 2 REGISTRY COPYRIGHT 2007 ACS on STN
RN 817204-38-9 REGISTRY
ED Entered STN: 20 Jan 2005
CN Cytidine, 2'-deoxy-2'-fluoro-2'-methyl-, monohydrochloride, (2'R)- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C10 H14 F N3 O4 . Cl H
SR CA
LC STN Files: CA, CAPLUS, PROUSDDR, SYNTHLINE, TOXCENTER, USPATFULL
CRN (817204-33-4)

Absolute stereochemistry. Rotation (+).



● HCl

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L3 ANSWER 2 OF 2 REGISTRY COPYRIGHT 2007 ACS on STN
RN 817204-33-4 REGISTRY
ED Entered STN: 20 Jan 2005
CN Cytidine, 2'-deoxy-2'-fluoro-2'-methyl-, (2'R)- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN PSI 6130
FS STEREOSEARCH
MF C10 H14 F N3 O4
CI COM
SR CA
LC STN Files: CA, CAPLUS, PROUSDDR, SYNTHLINE, TOXCENTER, USPATFULL

Absolute stereochemistry. Rotation (+).



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

4 REFERENCES IN FILE CA (1907 TO DATE)
4 REFERENCES IN FILE CAPLUS (1907 TO DATE)

McIntosh

09/582,315

=> file caplus
COST IN U.S. DOLLARS

	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	176.45	176.66

FILE 'CAPLUS' ENTERED AT 13:17:31 ON 19 MAR 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 19 Mar 2007 VOL 146 ISS 13
FILE LAST UPDATED: 18 Mar 2007 (20070318/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html

=> s l3
L4 4 L3

=> d bib abs hitstr 1-4 l4

L4 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2006:478128 CAPLUS
DN 145:202057
TI Inhibition of hepatitis C replicon RNA synthesis by β-D-2'-deoxy-2'-fluoro-2'-C-methylcytidine: a specific inhibitor of hepatitis C virus replication
AU Stuyver, Lieven J.; McBrayer, Tamara R.; Tharnish, Phillip M.; Clark, Jeremy; Hollecker, Laurent; Lostia, Stefania; Nachman, Tammy; Grier, Jason; Bennett, Matthew A.; Xie, Meng-Yu; Schinazi, Raymond F.; Morrey, John D.; Julander, Justin L.; Furman, Phillip A.; Otto, Michael J.
CS Pharmasset Inc, Princeton, NJ, USA
SO Antiviral Chemistry & Chemotherapy (2006), 17(2), 79-87
CODEN: ACCHEH; ISSN: 0956-3202
PB International Medical Press, Ltd.
DT Journal
LA English
AB β-D-2'-Deoxy-2'-fluoro-2'-C-methylcytidine (PSI-6130) is a cytidine analog with potent and selective anti-hepatitis C virus (HCV) activity in the subgenomic HCV replicon assay, 90% effective concentration (EC90) = 4.6 ± 2.0 μM. The spectrum of activity and cytotoxicity profile of PSI-6130 was evaluated against a diverse panel of viruses and cell types, and against two addnl. HCV-1b replicons. The S282T mutation, which confers resistance to 2'-C-Me adenosine and other 2'-methylated nucleosides, showed only a 6.5-fold increase in EC90. When assayed for activity against bovine diarrhoea virus (BVDV), which is typically used as a surrogate assay to identify compds. active against HCV, PSI-6130 showed no anti-BVDV activity. Weak antiviral activity was noted against other flaviviruses, including West Nile virus, Dengue type 2, and yellow fever virus. These results indicate that PSI-6130 is a specific inhibitor of HCV. PSI-6130 showed little or no cytotoxicity against various cell types, including human peripheral blood mononuclear and human bone marrow progenitor cells. No mitochondrial toxicity was observed with PSI-6130. The reduced activity against the RdRp S282T mutant suggests that PSI-6130 is an inhibitor of replicon RNA synthesis. Finally, the no-effect dose for mice treated i.p. with PSI-6130 for six consecutive days was ≥100 mg/kg per day.
IT 817204-33-4, PSI 6130
RL: ADV (Adverse effect, including toxicity); DMA (Drug mechanism of action); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

McIntosh

~~09/902,315~~

(PSI-6130 inhibition of hepatitis C replicon RNA synthesis)
RN 817204-33-4 CAPLUS
CN Cytidine, 2'-deoxy-2'-fluoro-2'-methyl-, (2'R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RE.CNT 36 THERE ARE 36 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2006:103884 CAPLUS
DN 144:171198
TI Preparation of alkyl-substituted 2-deoxy-2-fluoro-D-ribofuranosyl pyrimidine and purine nucleoside analogs via condensation of the lactone to nucleosides as potential antiviral agents
IN Wang, Peiyuan; Stec, Wojciech; Clark, Jeremy; Chun, Byoung-Kwon; Shi, Junxing; Du, Jinfa
PA Pharmasset, Inc., USA
SO PCT Int. Appl., 34 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2006012440	A2	20060202	WO 2005-US25916	20050721
	WO 2006012440	A3	20060727		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	US 2006199783	A1	20060907	US 2006-353597	20060213
PRAI	US 2004-589866P	P	20040721		
	US 2004-608320P	P	20040909		
	US 2005-185988	A1	20050721		

OS MARPAT 144:171198
GI

11/353,597
Claims to meth. of making cpds. in m/q.

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB A process for preparing of 2-deoxy-2-fluoro-2-methyl-D-ribonolactones, I, wherein R1 and R2 can independently be H, CH3, acetyl, benzoyl, pivaloyl, 4-nitrobenzoyl, 3-nitrobenzoyl, 2-nitrobenzoyl, 4-chlorobenzoyl, 3-chlorobenzoyl, 2-chlorobenzoyl, 4-methylbenzoyl, 3-methylbenzoyl, 2-methylbenzoyl, 4-phenylbenzoyl, benzyl, 4-methoxybenzyl, trityl, trialkylsilyl, t-butyl-dialkylsilyl, t-butyldiphenylsilyl, TIPDS, THP, MOM, or MEM are prepared and used in the condensation to 2-deoxy-2-fluoro-D-ribofuranosyl pyrimidine and purine nucleoside analogs. Thus, 2-deoxy-2-fluoro-D-ribofuranosyl pyrimidine and purine nucleoside analogs II and III, wherein X is a halogen; Y is N or CH; Z is a halogen, hydroxyl, ether, thiol, thioether, (un)substituted amine or alkyl; R1' is alkyl, vinyl, ethynyl; R2' and R3' can be same or different H, alkyl, arylalkyl, acyl, cyclic acetal such as 2',3'-O-isopropylidene or

2',3-O-benzylidene, or 2',3'-cyclic carbonate; R4, R5, and R6 are independently H, halogen, hydroxyl, ether, thiol, thioether, N3, (un)substituted amine, (un)substituted amido, alkyl, halogenated alkyl, alkenyl, halogenated alkenyl, alkynyl, halogenated alkynyl, hydroxy alkyl, alkoxy are prepared and are potential anti-HCV agents. Specifically, IV was prepared (no yield, claimed) via condensation, alkylation and stereoselective fluorination reactions and can exhibit potential use as an anti-HCV agent.

IT 817204-33-4P
RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP (Preparation)
(preparation of alkyl-substituted 2-deoxy-2-fluoro-D-ribofuranosyl pyrimidine and purine nucleoside analogs via condensation of the lactone to nucleosides)

RN 817204-33-4 CAPLUS
CN Cytidine, 2'-deoxy-2'-fluoro-2'-methyl-, (2'R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



L4 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2005:648160 CAPLUS
DN 143:248607
TI Design, Synthesis, and Antiviral Activity of 2'-Deoxy-2'-fluoro-2'-C-methyl-cytidine, a Potent Inhibitor of Hepatitis C Virus Replication
AU Clark, Jeremy L.; Hollecker, Laurent; Mason, J. Christian; Stuyver, Lieven J.; Tharnish, Phillip M.; Lostia, Stefania; McBrayer, Tamara R.; Schinazi, Raymond F.; Watanabe, Kyoichi A.; Otto, Michael J.; Furman, Phillip A.; Stec, Wojciech J.; Patterson, Steven E.; Pankiewicz, Krzysztof W.
CS Pharmasset, Inc., Princeton, NJ, 08540, USA
SO Journal of Medicinal Chemistry (2005), 48(17), 5504-5508
CODEN: JMCMAR; ISSN: 0022-2623
PB American Chemical Society
DT Journal
LA English
AB The pyrimidine nucleoside- β-D-2'-deoxy-2'-fluoro-2'-C-methylcytidine (I) was designed as a hepatitis C virus RNA-dependent RNA polymerase (HCV RdRp) inhibitor. The title compound was obtained by a DAST fluorination of N4-benzoyl-1-(2-methyl-3,5-di-O-benzoyl-β-D-arabinofuranosyl)cytosine to provide N4-benzoyl-1-(2-fluoro-2-methyl-3,5-di-O-benzoyl-β-D-ribofuranosyl)cytosine. The protected 2'-C-methylcytidine was obtained as a byproduct from the DAST fluorination and allowed for the preparation of two biol. active compds. from a common precursor. Compound I and 2'-C-methylcytidine were assayed in a sub-genomic HCV replicon assay system and found to be potent and selective inhibitors of HCV replication. Compd.I shows increased inhibitory activity in the HCV replicon assay compared to 2'-C-methylcytidine and low cellular toxicity.

IT 817204-33-4P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent)
(design, synthesis via fluorination, and antiviral activity of 2'-deoxy-2'-fluoro-2'-C-methyl-cytidine, a potent inhibitor of Hepatitis C virus replication)

RN 817204-33-4 CAPLUS
CN Cytidine, 2'-deoxy-2'-fluoro-2'-methyl-, (2'R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).

~~09/982,915~~



IT 817204-38-9P
RL: SPN (Synthetic preparation); PREP (Preparation)
(design, synthesis via fluorination, and antiviral activity of 2'-deoxy-2'-fluoro-2'-C-methyl-cytidine, a potent inhibitor of Hepatitis C virus replication)
RN 817204-38-9 CAPLUS
CN Cytidine, 2'-deoxy-2'-fluoro-2'-methyl-, monohydrochloride, (2'R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



● HCl

RE.CNT 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2005:34765 CAPLUS
DN 142:94074
TI Preparation of modified fluorinated (2'R)-2'-deoxy-2'-fluoro-2'-C-methyl nucleoside analogs as antiviral agents
IN Clark, Jeremy
PA Pharmasset, Ltd., Barbados
SO PCT Int. Appl., 228 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005003147	A2	20050113	WO 2004-US12472	20040421
	WO 2005003147	A3	20050303		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2004253860	A1	20050113	AU 2004-253860	20040421
	CA 2527657	A1	20050113	CA 2004-2527657	20040421
	US 2005009737	A1	20050113	US 2004-828753	20040421
	EP 1633766	A2	20060315	EP 2004-775900	20040421
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, HR				
	BR 2004010846	A	20060627	BR 2004-10846	20040421
	CN 1816558	A	20060809	CN 2004-80019148	20040421

McIntosh

	JP 2006526629	T	20061124	JP 2006-513231	20040421
	NO 2005006221	A	20051228	NO 2005-6221	20051228
PRAI	US 2003-474368P	P	20030530		
	WO 2004-US12472	W	20040421		

OS MARPAT 142:94074
GI



I

AB The disclosed invention provides nucleoside analogs I, wherein B is purine and pyrimidine nucleobase; X is O, S, CH2, Se, NH, N-alkyl, CHW, C(W)2; W is F, Cl, Br, iodo; R1 is H, phosphate, H-phosphonate, acyl, Ph, alkyl, carboxyalkylamino, sulfonate ester, peptide, amino acid, sugar reside; R2 and R2' are independently H, alkyl, alkenyl, alkynyl, vunyl, N3, CN, halogen, NO2, ester, alkoxy, thioalkyl, sulfoxide, sulfonyl; R6 is alkyl, CN, Me, OMe, OEt, CH2OH, CH2F, N3, CHCN, CH2N3, CH2NH2, CH2NHMe, CH2NMe2, alkylne; and methods of treating a Flaviviridae infection, including hepatitis C virus, West Nile Virus, yellow fever virus, and a rhinovirus infection in a host, including animals, and especially human, using a (2'R)-2'-deoxy-2'-fluoro-2'-C-Me nucleosides, or a pharmaceutically acceptable salt or prodrug thereof. Thus, (2'R)-2'-deoxy-2'-fluoro-2'-C-methylcytidine was prepared and tested as antiviral agent. The effects the nucleoside analogs tested on human bone marrow cells are reported. (2'R)-2'-deoxy-2'-fluoro-2'-C-methylcytidine shows activity against Rhinovirus, West Nile virus, Yellow Fever virus, and Dengue virus. Cytotoxicity and effect of nucleoside analogs on human bone marrow cells are reported.

IT 817204-33-4P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of modified fluorinated (2'R)-2'-deoxy-2'-fluoro-2'-C-Me nucleoside analogs as antiviral agents)

RN 817204-33-4 CAPLUS
CN Cytidine, 2'-deoxy-2'-fluoro-2'-methyl-, (2'R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



IT 817204-38-9P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of modified fluorinated (2'R)-2'-deoxy-2'-fluoro-2'-C-Me nucleoside analogs as antiviral agents)

RN 817204-38-9 CAPLUS
CN Cytidine, 2'-deoxy-2'-fluoro-2'-methyl-, monohydrochloride, (2'R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).

~~09/982,315~~



● HCl

=>

McIntosh

~~09/982,315~~

```
(FILE 'HOME' ENTERED AT 13:15:49 ON 19 MAR 2007)

     FILE 'REGISTRY' ENTERED AT 13:16:05 ON 19 MAR 2007
L1                STRUCTURE UPLOADED
L2              0 S L1 SSS SAM
L3              2 S L1 FULL

     FILE 'CAPLUS' ENTERED AT 13:17:31 ON 19 MAR 2007
L4              4 S L3
```

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:sssptal600txm

PASSWORD:
* * * * * * RECONNECTED TO STN INTERNATIONAL * * * * * *
SESSION RESUMED IN FILE 'REGISTRY' AT 14:10:13 ON 19 MAR 2007
FILE 'REGISTRY' ENTERED AT 14:10:13 ON 19 MAR 2007
COPYRIGHT (C) 2007 American Chemical Society (ACS)

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	174.80	547.44

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-3.12

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	174.80	547.44

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-3.12

FILE 'REGISTRY' ENTERED AT 14:10:25 ON 19 MAR 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 16 MAR 2007 HIGHEST RN 926905-73-9
DICTIONARY FILE UPDATES: 16 MAR 2007 HIGHEST RN 926905-73-9

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH December 2, 2006

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

=>
Uploading C:\Program Files\Stnexp\Queries\10828753cl6-11c.str

L15 STRUCTURE UPLOADED

=> s l15 sss sam
SAMPLE SEARCH INITIATED 14:10:45 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 10 TO ITERATE

100.0% PROCESSED 10 ITERATIONS 0 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:	ONLINE	**COMPLETE**
	BATCH	**COMPLETE**
PROJECTED ITERATIONS:	11 TO	389
PROJECTED ANSWERS:	0 TO	0

10/828,753

L16 0 SEA SSS SAM L15

=> s l15 full
FULL SEARCH INITIATED 14:10:52 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 148 TO ITERATE

100.0% PROCESSED 148 ITERATIONS 11 ANSWERS
SEARCH TIME: 00.00.01

L17 11 SEA SSS FUL L15

=> file caplus
COST IN U.S. DOLLARS SINCE FILE ENTRY TOTAL SESSION
FULL ESTIMATED COST 172.10 719.54

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS) SINCE FILE ENTRY TOTAL SESSION
CA SUBSCRIBER PRICE 0.00 -3.12

FILE 'CAPLUS' ENTERED AT 14:10:58 ON 19 MAR 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 19 Mar 2007 VOL 146 ISS 13
FILE LAST UPDATED: 18 Mar 2007 (20070318/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html

=> s l17
L18 6 L17

=> d bib abs hitstr 1-6 l18

L18 ANSWER 1 OF 6 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2006:985303 CAPLUS
DN 145:505687
TI Synthesis of 2-deoxy-2-fluoro-2-C-methyl-D-ribofuranoses
AU Clark, Jeremy L.; Mason, J. Christian; Hobbs, Ann J.; Hollecker, Laurent; Schinazi, Raymond F.
CS Pharmasset, Inc., Tucker, GA, USA
SO Journal of Carbohydrate Chemistry (2006), 25(6), 461-470
CODEN: JCACDM; ISSN: 0732-8303
PB Taylor & Francis, Inc.
DT Journal
LA English
AB The synthesis of Me 3,5-di-O-benzoyl-2-deoxy-2-fluoro-2-C-methyl-β-D-ribofuranoside and the conversion to the corresponding 1-O-acetyl-3,5-di-O-benzoyl-2-deoxy-2-fluoro-2-C-methyl-D-ribofuranose and 1,3,5-tri-O-benzoyl-2-deoxy-2-fluoro-2-C-methyl-D-ribofuranose is reported. The key synthetic step is the fluorination of the tertiary center of Me 3,5-di-O-benzyl-2-C-methyl-β-D-arabinofuranoside to provide Me 3,5-di-O-benzyl-2-deoxy-2-fluoro-2-C-methyl-β-D-ribofuranoside.
IT 817204-32-3P 874638-94-5P
RL: SPN (Synthetic preparation); PREP (Preparation)
(synthesis of 2-deoxy-2-fluoro-2-C-methyl-D-ribofuranoses via fluorination of the tertiary center of Me 3,5-di-O-benzyl-2-C-methyl-β-D-arabinofuranosides)
RN 817204-32-3 CAPLUS

McIntosh

CN Cytidine, N-benzoyl-2'-deoxy-2'-fluoro-2'-methyl-, 3',5'-dibenzoate, (2'R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 874638-94-5 CAPLUS
CN Benzamide, N-[1-[(2R)-3,5-di-O-benzoyl-2-deoxy-2-fluoro-2-methyl-α-D-erythro-pentofuranosyl]-1,2-dihydro-2-oxo-4-pyrimidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 20 THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2006:478128 CAPLUS
DN 145:202057
TI Inhibition of hepatitis C replicon RNA synthesis by β-D-2'-deoxy-2'-fluoro-2'-C-methylcytidine: a specific inhibitor of hepatitis C virus replication
AU Stuyver, Lieven J.; McBrayer, Tamara R.; Tharnish, Phillip M.; Clark, Jeremy; Hollecker, Laurent; Lostia, Stefania; Nachman, Tammy; Grier, Jason; Bennett, Matthew A.; Xie, Meng-Yu; Schinazi, Raymond F.; Morrey, John D.; Julander, Justin L.; Furman, Phillip A.; Otto, Michael J.
CS Pharmasset Inc, Princeton, NJ, USA
SO Antiviral Chemistry & Chemotherapy (2006), 17(2), 79-87
CODEN: ACCHEH; ISSN: 0956-3202
PB International Medical Press, Ltd.
DT Journal
LA English
AB β-D-2'-Deoxy-2'-fluoro-2'-C-methylcytidine (PSI-6130) is a cytidine analog with potent and selective anti-hepatitis C virus (HCV) activity in the subgenomic HCV replicon assay, 90% effective concentration (EC90) = 4.6 ± 2.0 μM. The spectrum of activity and cytotoxicity profile of PSI-6130 was evaluated against a diverse panel of viruses and cell types, and against two addnl. HCV-1b replicons. The S282T mutation, which confers resistance to 2'-C-Me adenosine and other 2'-methylated nucleosides, showed only a 6.5-fold increase in EC90. When assayed for activity against bovine diarrhoea virus (BVDV), which is typically used as a surrogate assay to identify compds. active against HCV, PSI-6130 showed no anti-BVDV activity. Weak antiviral activity was noted against other flaviviruses, including West Nile virus, Dengue type 2, and yellow fever virus. These results indicate that PSI-6130 is a specific inhibitor of HCV. PSI-6130 showed little or no cytotoxicity against various cell types, including human peripheral blood mononuclear and human bone marrow progenitor cells. No mitochondrial toxicity was observed with PSI-6130. The

reduced activity against the RdRp S282T mutant suggests that PSI-6130 is an inhibitor of replicon RNA synthesis. Finally, the no-effect dose for mice treated i.p. with PSI-6130 for six consecutive days was ≥100 mg/kg per day.

IT 817204-33-4, PSI 6130
RL: ADV (Adverse effect, including toxicity); DMA (Drug mechanism of action); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(PSI-6130 inhibition of hepatitis C replicon RNA synthesis)

RN 817204-33-4 CAPLUS

CN Cytidine, 2'-deoxy-2'-fluoro-2'-methyl-, (2'R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RE.CNT 36 THERE ARE 36 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2006:269477 CAPLUS

DN 144:312289

TI Preparation of alkyl-substituted 2-deoxy-2-fluoro-D-ribofuranosyl pyrimidine and purine nucleoside analogs via condensation of the lactone to nucleosides as potential antiviral agents

IN Chun, Byoung-Kwon; Wang, Peiyuan

PA Pharmasset, Inc., USA

SO PCT Int. Appl., 74 pp.
CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2006031725	A2	20060323	WO 2005-US32406	20050913
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	US 2006122146	A1	20060608	US 2005-225425	20050913
PRAI	US 2004-609783P	P	20040914		
	US 2004-610035P	P	20040915		
	US 2005-666230P	P	20050329		

OS MARPAT 144:312289

GI

11/225,425

claims to making

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB A process for preparing of 2-deoxy-2-fluoro-2-methyl-D-ribonolactones, I, wherein R1 and R2 can independently be H, CH3, acetyl, benzoyl, pivaloyl, 4-nitrobenzoyl, 3-nitrobenzoyl, 2-nitrobenzoyl, 4-chlorobenzoyl, 3-chlorobenzoyl, 2-chlorobenzoyl, 4-methylbenzoyl, 3-methylbenzoyl, 2-methylbenzoyl, 4-phenylbenzoyl, benzyl, 4-methoxybenzyl, trityl, trialkylsilyl, t-butyl-dialkylsilyl, t-butyldiphenylsilyl, TIPDS, THP, MOM, or MEM are prepared and used in the condensation to

2-deoxy-2-fluoro-D-ribofuranosyl pyrimidine and purine nucleoside analogs. Thus, 2-deoxy-2-fluoro-D-ribofuranosyl pyrimidine and purine nucleoside analogs II and III, wherein X is a halogen; Y is N or CH; Z is a halogen, hydroxyl, ether, thiol, thioether, (un)substituted amine or alkyl; R1' is alkyl, vinyl, ethynyl; R2' and R3' can be same or different H, alkyl, arylalkyl, acyl, cyclic acetal such as 2',3'-O-isopropylidene or 2',3-O-benzylidene, or 2',3'-cyclic carbonate; R4, R5, and R6 are independently H, halogen, hydroxyl, ether, thiol, thioether, N3, (un)substituted amine, (un)substituted amido, alkyl, halogenated alkyl, alkenyl, halogenated alkenyl, alkynyl, halogenated alkynyl, hydroxy alkyl, alkoxy are prepared and are potential anti-HCV agents. Specifically, IV was prepared in 88 % yield via condensation, alkylation and stereoselective fluorination reactions and can exhibit potential use as an anti-HCV agent.

IT 879551-07-2P
RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP (Preparation)
(preparation of alkyl-substituted 2-deoxy-2-fluoro-D-ribofuranosyl pyrimidine and purine nucleoside analogs via condensation of the lactone to nucleosides)

RN 879551-07-2 CAPLUS
CN Cytidine, N-benzoyl-2'-deoxy-2'-fluoro-2'-methyl-, 3',5'-bis(2,2-dimethylpropanoate), (2'R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L18 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2006:103884 CAPLUS
DN 144:171198
TI Preparation of alkyl-substituted 2-deoxy-2-fluoro-D-ribofuranosyl pyrimidine and purine nucleoside analogs via condensation of the lactone to nucleosides as potential antiviral agents
IN Wang, Peiyuan; Stec, Wojciech; Clark, Jeremy; Chun, Byoung-Kwon; Shi, Junxing; Du, Jinfa
PA Pharmasset, Inc., USA
SO PCT Int. Appl., 34 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2006012440	A2	20060202	WO 2005-US25916	20050721
	WO 2006012440	A3	20060727		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	US 2006199783	A1	20060907	US 2006-353597	20060213
PRAI	US 2004-589866P	P	20040721		
	US 2004-608320P	P	20040909		
	US 2005-185988	A1	20050721		
OS	MARPAT 144:171198				

11/353,597

GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB A process for preparing of 2-deoxy-2-fluoro-2-methyl-D-ribonolactones, I, wherein R1 and R2 can independently be H, CH3, acetyl, benzoyl, pivaloyl, 4-nitrobenzoyl, 3-nitrobenzoyl, 2-nitrobenzoyl, 4-chlorobenzoyl, 3-chlorobenzoyl, 2-chlorobenzoyl, 4-methylbenzoyl, 3-methylbenzoyl, 2-methylbenzoyl, 4-phenylbenzoyl, benzyl, 4-methoxybenzyl, trityl, trialkylsilyl, t-butyl-dialkylsilyl, t-butyldiphenylsilyl, TIPDS, THP, MOM, or MEM are prepared and used in the condensation to 2-deoxy-2-fluoro-D-ribofuranosyl pyrimidine and purine nucleoside analogs. Thus, 2-deoxy-2-fluoro-D-ribofuranosyl pyrimidine and purine nucleoside analogs II and III, wherein X is a halogen; Y is N or CH; Z is a halogen, hydroxyl, ether, thiol, thioether, (un)substituted amine or alkyl; R1' is alkyl, vinyl, ethynyl; R2' and R3' can be same or different H, alkyl, arylalkyl, acyl, cyclic acetal such as 2',3'-O-isopropylidene or 2',3-O-benzylidene, or 2',3'-cyclic carbonate; R4, R5, and R6 are independently H, halogen, hydroxyl, ether, thiol, thioether, N3, (un)substituted amine, (un)substituted amido, alkyl, halogenated alkyl, alkenyl, halogenated alkenyl, alkynyl, halogenated alkynyl, hydroxy alkyl, alkoxy are prepared and are potential anti-HCV agents. Specifically, IV was prepared (no yield, claimed) via condensation, alkylation and stereoselective fluorination reactions and can exhibit potential use as an anti-HCV agent.

IT 817204-32-3P 817204-33-4P 874638-82-1P
874638-94-5P 874638-98-9P
RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP (Preparation)
(preparation of alkyl-substituted 2-deoxy-2-fluoro-D-ribofuranosyl pyrimidine and purine nucleoside analogs via condensation of the lactone to nucleosides)

RN 817204-32-3 CAPLUS

CN Cytidine, N-benzoyl-2'-deoxy-2'-fluoro-2'-methyl-, 3',5'-dibenzoate, (2'R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 817204-33-4 CAPLUS

CN Cytidine, 2'-deoxy-2'-fluoro-2'-methyl-, (2'R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 874638-82-1 CAPLUS

CN Benzamide, N-[1-[(2R)-5-O-benzoyl-2-deoxy-2-fluoro-2-methyl-3-O-(methylsulfonyl)-β-D-erythro-pentofuranosyl]-1,2-dihydro-2-oxo-4-pyrimidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 874638-94-5 CAPLUS
CN Benzamide, N-[1-[(2R)-3,5-di-O-benzoyl-2-deoxy-2-fluoro-2-methyl-α-D-erythro-pentofuranosyl]-1,2-dihydro-2-oxo-4-pyrimidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 874638-98-9 CAPLUS
CN Cytidine, N-benzoyl-2'-deoxy-2'-fluoro-2'-methyl-, (2'R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L18 ANSWER 5 OF 6 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2005:648160 CAPLUS
DN 143:248607
TI Design, Synthesis, and Antiviral Activity of 2'-Deoxy-2'-fluoro-2'-C-methyl-cytidine, a Potent Inhibitor of Hepatitis C Virus Replication
AU Clark, Jeremy L.; Hollecker, Laurent; Mason, J. Christian; Stuyver, Lieven J.; Tharnish, Phillip M.; Lostia, Stefania; McBrayer, Tamara R.; Schinazi, Raymond F.; Watanabe, Kyoichi A.; Otto, Michael J.; Furman, Phillip A.; Stec, Wojciech J.; Patterson, Steven E.; Pankiewicz, Krzysztof W.
CS Pharmasset, Inc., Princeton, NJ, 08540, USA
SO Journal of Medicinal Chemistry (2005), 48(17), 5504-5508
CODEN: JMCMAR; ISSN: 0022-2623
PB American Chemical Society
DT Journal
LA English
AB The pyrimidine nucleoside- β-D-2'-deoxy-2'-fluoro-2'-C-methylcytidine (I) was designed as a hepatitis C virus RNA-dependent RNA polymerase (HCV RdRp) inhibitor. The title compound was obtained by a DAST fluorination of

N4-benzoyl-1-(2-methyl-3,5-di-O-benzoyl-β-D-arabinofuranosyl)cytosine to provide N4-benzoyl-1-(2-fluoro-2-methyl-3,5-di-O-benzoyl-β-D-ribofuranosyl)cytosine. The protected 2'-C-methylcytidine was obtained as a byproduct from the DAST fluorination and allowed for the preparation of two biol. active compds. from a common precursor. Compound I and 2'-C-methylcytidine were assayed in a sub-genomic HCV replicon assay system and found to be potent and selective inhibitors of HCV replication. Compd.I shows increased inhibitory activity in the HCV replicon assay compared to 2'-C-methylcytidine and low cellular toxicity.

IT 817204-33-4P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent)
(design, synthesis via fluorination, and antiviral activity of 2'-deoxy-2'-fluoro-2'-C-methyl-cytidine, a potent inhibitor of Hepatitis C virus replication)
RN 817204-33-4 CAPLUS
CN Cytidine, 2'-deoxy-2'-fluoro-2'-methyl-, (2'R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



IT 863329-66-2P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(design, synthesis via fluorination, and antiviral activity of 2'-deoxy-2'-fluoro-2'-C-methyl-cytidine, a potent inhibitor of Hepatitis C virus replication)
RN 863329-66-2 CAPLUS
CN Uridine, 2'-deoxy-2'-fluoro-2'-methyl-, (2'R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



IT 817204-32-3P 863329-65-1P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(design, synthesis via fluorination, and antiviral activity of 2'-deoxy-2'-fluoro-2'-C-methyl-cytidine, a potent inhibitor of Hepatitis C virus replication)
RN 817204-32-3 CAPLUS
CN Cytidine, N-benzoyl-2'-deoxy-2'-fluoro-2'-methyl-, 3',5'-dibenzoate, (2'R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 863329-65-1 CAPLUS
CN Uridine, 2'-deoxy-2'-fluoro-2'-methyl-, 3',5'-dibenzoate, (2'R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



IT 817204-38-9P
RL: SPN (Synthetic preparation); PREP (Preparation)
(design, synthesis via fluorination, and antiviral activity of 2'-deoxy-2'-fluoro-2'-C-methyl-cytidine, a potent inhibitor of Hepatitis C virus replication)
RN 817204-38-9 CAPLUS
CN Cytidine, 2'-deoxy-2'-fluoro-2'-methyl-, monohydrochloride, (2'R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



● HCl

RE.CNT 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 6 OF 6 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2005:34765 CAPLUS
DN 142:94074
TI Preparation of modified fluorinated (2'R)-2'-deoxy-2'-fluoro-2'-C-methyl nucleoside analogs as antiviral agents
IN Clark, Jeremy
PA Pharmasset, Ltd., Barbados
SO PCT Int. Appl., 228 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1
PATENT NO. KIND DATE APPLICATION NO. DATE

PI	WO 2005003147	A2	20050113	WO 2004-US12472	20040421
	WO 2005003147	A3	20050303		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2004253860	A1	20050113	AU 2004-253860	20040421
	CA 2527657	A1	20050113	CA 2004-2527657	20040421
	US 2005009737	A1	20050113	US 2004-828753	20040421
	EP 1633766	A2	20060315	EP 2004-775900	20040421
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, HR				
	BR 2004010846	A	20060627	BR 2004-10846	20040421
	CN 1816558	A	20060809	CN 2004-80019148	20040421
	JP 2006526629	T	20061124	JP 2006-513231	20040421
	NO 2005006221	A	20051228	NO 2005-6221	20051228
PRAI	US 2003-474368P	P	20030530		
	WO 2004-US12472	W	20040421		

OS MARPAT 142:94074

GI



I

AB The disclosed invention provides nucleoside analogs I, wherein B is purine and pyrimidine nucleobase; X is O, S, CH2, Se, NH, N-alkyl, CHW, C(W)2; W is F, Cl, Br, iodo; R1 is H, phosphate, H-phosphonate, acyl, Ph, alkyl, carboxyalkylamino, sulfonate ester, peptide, amino acid, sugar reside; R2 and R2' are independently H, alkyl, alkenyl, alkynyl, vunyl, N3, CN, halogen, NO2, ester, alkoxy, thioalkyl, sulfoxide, sulfonyl; R6 is alkyl, CN, Me, OMe, OEt, CH2OH, CH2F, N3, CHCN, CH2N3, CH2NH2, CH2NHMe, CH2NMe2, alkylne; and methods of treating a Flaviviridae infection, including hepatitis C virus, West Nile Virus, yellow fever virus, and a rhinovirus infection in a host, including animals, and especially human, using a (2'R)-2'-deoxy-2'-fluoro-2'-C-Me nucleosides, or a pharmaceutically acceptable salt or prodrug thereof. Thus, (2'R)-2'-deoxy-2'-fluoro-2'-C-methylcytidine was prepared and tested as antiviral agent. The effects the nucleoside analogs tested on human bone marrow cells are reported. (2'R)-2'-deoxy-2'-fluoro-2'-C-methylcytidine shows activity against Rhinovirus, West Nile virus, Yellow Fever virus, and Dengue virus. Cytotoxicity and effect of nucleoside analogs on human bone marrow cells are reported.

IT 817204-33-4P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of modified fluorinated (2'R)-2'-deoxy-2'-fluoro-2'-C-Me nucleoside analogs as antiviral agents)

RN 817204-33-4 CAPLUS

CN Cytidine, 2'-deoxy-2'-fluoro-2'-methyl-, (2'R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



IT 817204-38-9P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of modified fluorinated (2'R)-2'-deoxy-2'-fluoro-2'-C-Me nucleoside analogs as antiviral agents)
RN 817204-38-9 CAPLUS
CN Cytidine, 2'-deoxy-2'-fluoro-2'-methyl-, monohydrochloride, (2'R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



● HCl

IT 817204-44-7
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(preparation of modified fluorinated (2'R)-2'-deoxy-2'-fluoro-2'-C-Me nucleoside analogs as antiviral agents)
RN 817204-44-7 CAPLUS
CN Cytidine 5'-(tetrahydrogen triphosphate), 2'-deoxy-2'-fluoro-2'-methyl-, (2'R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 817204-32-3P 817204-37-8P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of modified fluorinated (2'R)-2'-deoxy-2'-fluoro-2'-C-Me nucleoside analogs as antiviral agents)
RN 817204-32-3 CAPLUS
CN Cytidine, N-benzoyl-2'-deoxy-2'-fluoro-2'-methyl-, 3',5'-dibenzoate, (2'R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 817204-37-8 CAPLUS
CN Cytidine, N-benzoyl-2'-deoxy-2'-fluoro-2'-methyl-, 3',5'-bis(trifluoroacetate), (2'R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



=> d his

(FILE 'HOME' ENTERED AT 13:15:49 ON 19 MAR 2007)

FILE 'REGISTRY' ENTERED AT 13:16:05 ON 19 MAR 2007
L1 STRUCTURE UPLOADED
L2 0 S L1 SSS SAM
L3 2 S L1 FULL

FILE 'CAPLUS' ENTERED AT 13:17:31 ON 19 MAR 2007
L4 4 S L3

FILE 'REGISTRY' ENTERED AT 13:42:33 ON 19 MAR 2007
L5 STRUCTURE UPLOADED
L6 0 S L5 SSS SAM
L7 0 S L5 FULL

FILE 'REGISTRY' ENTERED AT 14:04:04 ON 19 MAR 2007
L8 STRUCTURE UPLOADED
L9 0 S L8 SSS SAM
L10 0 S L8 FULL
L11 STRUCTURE UPLOADED
L12 0 S L11 SSS SAM
L13 STRUCTURE UPLOADED
L14 0 S L13 SSS SAM

FILE 'REGISTRY' ENTERED AT 14:10:25 ON 19 MAR 2007
L15 STRUCTURE UPLOADED
L16 0 S L15 SSS SAM
L17 11 S L15 FULL

FILE 'CAPLUS' ENTERED AT 14:10:58 ON 19 MAR 2007
L18 6 S L17

```
=> s us 20050009737/pn
L19           1 US 20050009737/PN
                (US2005009737/PN)

=> sel rn
E1 THROUGH E32 ASSIGNED

=> file reg
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                    35.12     754.66

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                       ENTRY    SESSION
CA SUBSCRIBER PRICE                                    -4.68      -7.80

FILE 'REGISTRY' ENTERED AT 14:12:43 ON 19 MAR 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   16 MAR 2007  HIGHEST RN 926905-73-9
DICTIONARY FILE UPDATES:  16 MAR 2007  HIGHEST RN 926905-73-9

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH December 2, 2006

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

=> s e1-e32
             1 103285-18-3/BI
               (103285-18-3/RN)
             1 119411-03-9/BI
               (119411-03-9/RN)
             1 129932-37-2/BI
               (129932-37-2/RN)
             1 13089-48-0/BI
               (13089-48-0/RN)
             1 15397-12-3/BI
               (15397-12-3/RN)
             1 20724-73-6/BI
               (20724-73-6/RN)
             1 374750-27-3/BI
               (374750-27-3/RN)
             1 374750-28-4/BI
               (374750-28-4/RN)
             1 5399-87-1/BI
               (5399-87-1/RN)
             1 64339-87-3/BI
               (64339-87-3/RN)
             1 65-46-3/BI
               (65-46-3/RN)
             1 69304-37-6/BI
               (69304-37-6/RN)
             1 69304-43-4/BI
               (69304-43-4/RN)
             1 817204-28-7/BI
               (817204-28-7/RN)
             1 817204-29-8/BI
               (817204-29-8/RN)
             1 817204-30-1/BI
               (817204-30-1/RN)
             1 817204-31-2/BI
```

(817204-31-2/RN)
1 817204-32-3/BI
(817204-32-3/RN)
1 817204-33-4/BI
(817204-33-4/RN)
1 817204-34-5/BI
(817204-34-5/RN)
1 817204-35-6/BI
(817204-35-6/RN)
1 817204-36-7/BI
(817204-36-7/RN)
1 817204-37-8/BI
(817204-37-8/RN)
1 817204-38-9/BI
(817204-38-9/RN)
1 817204-39-0/BI
(817204-39-0/RN)
1 817204-40-3/BI
(817204-40-3/RN)
1 817204-41-4/BI
(817204-41-4/RN)
1 817204-42-5/BI
(817204-42-5/RN)
1 817204-43-6/BI
(817204-43-6/RN)
1 817204-44-7/BI
(817204-44-7/RN)
1 817204-45-8/BI
(817204-45-8/RN)
1 9026-28-2/BI
(9026-28-2/RN)

L20 32 (103285-18-3/BI OR 119411-03-9/BI OR 129932-37-2/BI OR 13089-48-0/BI OR 15397-12-3/BI OR 20724-73-6/BI OR 374750-27-3/BI OR 374750-28-4/BI OR 5399-87-1/BI OR 64339-87-3/BI OR 65-46-3/BI OR 69304-37-6/BI OR 69304-43-4/BI OR 817204-28-7/BI OR 817204-29-8/BI OR 817204-30-1/BI OR 817204-31-2/BI OR 817204-32-3/BI OR 817204-33-4/BI OR 817204-34-5/BI OR 817204-35-6/BI OR 817204-36-7/BI OR 817204-37-8/BI OR 817204-38-9/BI OR 817204-39-0/BI OR 817204-40-3/BI OR 817204-41-4/BI OR 817204-42-5/BI OR 817204-43-6/BI OR 817204-44-7/BI OR 817204-45-8/BI OR 9026-28-2/BI)

=> d scan 120

L20 32 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Nucleotidyltransferase, ribonucleate, RNA-dependent (9CI)
MF Unspecified
CI MAN

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):31

L20 32 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Cytidine, N-benzoyl- (7CI, 9CI)
MF C16 H17 N3 O6
CI COM

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

McIntosh

L20 32 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Adenosine, 2'-C-methyl- (8CI, 9CI)
MF C11 H15 N5 O4

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L20 32 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Cytidine, 2'-C-methyl- (8CI, 9CI)
MF C10 H15 N3 O5

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L20 32 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Benzamide, N-(trimethylsilyl)-N-[2-[(trimethylsilyl)oxy]-4-pyrimidinyl]- (9CI)
MF C17 H25 N3 O2 Si2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L20 32 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Disiloxane, 1,3-dichloro-1,1,3,3-tetrakis(1-methylethyl)-
MF C12 H28 Cl2 O Si2
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L20 32 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Cytidine, N-benzoyl-3',5'-O-[1,1,3,3-tetrakis(1-methylethyl)-1,3-disiloxanediyl]- (9CI)
MF C28 H43 N3 O7 Si2

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L20 32 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 9H-Purine, 6-chloro-9-[3,5-O-[1,1,3,3-tetrakis(1-methylethyl)-1,3-disiloxanediyl]-β-D-ribofuranosyl]- (9CI)
MF C22 H37 Cl N4 O5 Si2

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L20 32 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Cytidine, N-benzoyl-2'-deoxy-2'-oxo-3',5'-O-[1,1,3,3-tetrakis(1-methylethyl)-1,3-disiloxanediyl]- (9CI)
MF C28 H41 N3 O7 Si2

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L20 32 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 9H-Purine, 6-chloro-9-[3,5-O-[1,1,3,3-tetrakis(1-methylethyl)-1,3-disiloxanediyl]-β-D-erythro-pentofuranos-2-ulos-1-yl]- (9CI)
MF C22 H35 Cl N4 O5 Si2

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L20 32 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Adenosine 5'-(tetrahydrogen triphosphate), 2'-C-methyl- (9CI)
MF C11 H18 N5 O13 P3

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L20 32 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Cytidine 5'-(tetrahydrogen triphosphate), 2'-C-methyl- (9CI)
MF C10 H18 N3 O14 P3

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L20 32 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN β-D-erythro-Pentofuranosid-2-ulose, methyl 3,5-bis-O-(phenylmethyl)-(9CI)
MF C20 H22 O5

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L20 32 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN β-D-Arabinofuranoside, methyl 2-C-methyl-3,5-bis-O-(phenylmethyl)-(9CI)
MF C21 H26 O5

Absolute stereochemistry. .



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L20 32 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN β-D-erythro-Pentofuranoside, methyl 2-deoxy-2-fluoro-2-methyl-3,5-bis-O-(phenylmethyl)-, (2R)- (9CI)
MF C21 H25 F O4

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L20 32 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN β-D-erythro-Pentofuranoside, methyl 2-deoxy-2-fluoro-2-methyl-, dibenzoate, (2R)- (9CI)
MF C21 H21 F O6

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L20 32 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Cytidine, N-benzoyl-2'-deoxy-2'-fluoro-2'-methyl-, 3',5'-dibenzoate, (2'R)- (9CI)
MF C31 H26 F N3 O7

Absolute stereochemistry. Rotation (+).



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L20 32 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Cytidine, 2'-deoxy-2'-fluoro-2'-methyl-, (2'R)- (9CI)
MF C10 H14 F N3 O4
CI COM

Absolute stereochemistry. Rotation (+).



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L20 32 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Benzamide, N-[1,2-dihydro-1-[2-C-methyl-3,5-O-[1,1,3,3-tetrakis(1-methylethyl)-1,3-disiloxanediyl]-β-D-arabinofuranosyl]-2-oxo-4-pyrimidinyl]- (9CI)

MF C29 H45 N3 O7 Si2

Absolute stereochemistry. Rotation (+).



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L20 32 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Benzamide, N-[1,2-dihydro-1-(2-C-methyl-β-D-arabinofuranosyl)-2-oxo-4-pyrimidinyl]- (9CI)
MF C17 H19 N3 O6

Absolute stereochemistry. Rotation (+).



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L20 32 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Benzamide, N-[1,2-dihydro-1-[2-C-methyl-3,5-bis-O-(trifluoroacetyl)-β-D-arabinofuranosyl]-2-oxo-4-pyrimidinyl]- (9CI)
MF C21 H17 F6 N3 O8

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

McIntosh

L20 32 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Cytidine, N-benzoyl-2'-deoxy-2'-fluoro-2'-methyl-, 3',5'-bis(trifluoroacetate), (2'R)- (9CI)
MF C21 H16 F7 N3 O7

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L20 32 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Cytidine, 2'-deoxy-2'-fluoro-2'-methyl-, monohydrochloride, (2'R)- (9CI)
MF C10 H14 F N3 O4 . Cl H

Absolute stereochemistry. Rotation (+).



● HCl

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L20 32 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 9H-Purine, 6-chloro-9-(2-C-methyl-β-D-arabinofuranosyl)- (9CI)
MF C11 H13 Cl N4 O4

Absolute stereochemistry.



McIntosh

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L20 32 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 9H-Purine, 6-chloro-9-(3,5-di-O-acetyl-2-C-methyl-β-D-arabinofuranosyl)- (9CI)
MF C15 H17 Cl N4 O6

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L20 32 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 9H-Purine, 6-chloro-9-[(2R)-3,5-di-O-acetyl-2-deoxy-2-fluoro-2-methyl-β-D-erythro-pentofuranosyl]- (9CI)
MF C15 H16 Cl F N4 O5

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L20 32 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 9H-Purine, 6-chloro-9-[(2R)-2-deoxy-2-fluoro-2-methyl-β-D-erythro-pentofuranosyl]- (9CI)
MF C11 H12 Cl F N4 O3

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L20 32 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Adenosine, 2'-deoxy-2'-fluoro-2'-methyl-, monohydrochloride, (2'R)- (9CI)
MF C11 H14 F N5 O3 . Cl H

Absolute stereochemistry.



● HCl

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L20 32 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Cytidine 5'-(tetrahydrogen triphosphate), 2'-deoxy-2'-fluoro-2'-methyl-, (2'R)- (9CI)
MF C10 H17 F N3 O13 P3

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L20 32 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Guanosine, 2'-deoxy-2'-fluoro-2'-methyl-, (2'R)- (9CI)
MF C11 H14 F N5 O4

Absolute stereochemistry.

McIntosh



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L20 32 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Cytidine (8CI, 9CI)
MF C9 H13 N3 O5
CI COM

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L20 32 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 9H-Purine, 6-chloro-9-β-D-ribofuranosyl- (6CI, 7CI, 8CI, 9CI)
MF C10 H11 Cl N4 O4
CI COM

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

ALL ANSWERS HAVE BEEN SCANNED